Copenhagen, 15 September 2010 - NeuroSearch (NEUR) informed today that the
company will present at the UBS 2010 Global Life Science conference which takes
place from 20-22 September 2010 at the Grand Hyatt New York hotel, New York
City.

The NeuroSearch presentation is scheduled for

Tuesday, 21 September at 10.00 am local time

and will be held by Hanne Leth Hillman, Vice President, Director of Investor &
Capital Market Relations.

The related PowerPoint presentation will be available at the company's website;
www.neurosearch.com just prior to the presentation being held at the
conference.

The UBS Global Life Science conference features representatives from
approximately 300 companies in the following sectors: Biotechnology, Life
Sciences Tools, Medical Technology, Pharmaceuticals and Specialty
Pharmaceuticals.

For more information about the conference, please visit
www.ibb.ubs.com/Conferences.


Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103


About NeuroSearch - Company profile
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel treatment of obesity.

NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery alliances with Janssen Pharmaceutica and Eli Lilly as
well as a licence collaboration with Abbott. Further, NeuroSearch has equity
interests in a number of private companies in the Life Science industry.